Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19.
暂无分享，去创建一个
David T. Huang | C. Seymour | D. Yealy | G. Snyder | D. Angus | K. Kip | O. Marroquin | S. Berry | A. McGlothlin | M. Schmidhofer | D. Huang | E. McCreary | J. Bariola | T. Minnier | R. J. Wadas | J. Shovel | D. Albin | M. Wisniewski | R. Meyers | W. Garrard | K. Collins | K. Linstrum | S. Montgomery | D. Yealy | M. Adam | A. Crawford | P. L. Kip | Amy Crawford | De Angus | E. McCreary | Michelle Adam | Anna Nakayama | A. Nakayama | S. Berry | R. Meyers | L. R. Berrry | Lindsay R. Berrry